Enanta Pharmaceuticals, Inc

Enanta Pharmaceuticals is a U.S.-based biotechnology company focused on discovering and developing small-molecule drugs in virology and immunology. Its business currently combines royalty income from AbbVie’s HCV franchise with an internal pipeline spanning RSV, hepatitis B, and type 2 inflammatory diseases such as atopic dermatitis and CSU.

−123,6 %

−125,4 %

−3,4 %

4.21

4.21

— Enanta Pharmaceuticals, Inc
%
Royalty revenue from AbbVie collaboration100% Cash royalties tied to AbbVie sales of MAVYRET/MAVIRET, based on Enanta's licensed HCV protease inhibitor assets.
RSV antiviral pipeline0% Clinical-stage programs aimed at treating respiratory syncytial virus infection, including zelicapavir and EDP-323.
Immunology discovery programs0% Preclinical small-molecule programs targeting type 2 immune diseases through STAT6 inhibition.
Business development and licensing0% In-licensing, out-licensing, and collaboration activities that monetize or expand the pipeline.

Enanta does not currently sell approved products directly to patients or physicians; its near-term commercial customer...

  • AbbVie collaboration partnerprimary

    AbbVie commercializes MAVYRET/MAVIRET and pays Enanta royalties tied to HCV sales.

  • Future RSV treatment prescriberssecondary

    Physicians, hospitals, and clinics that would prescribe zelicapavir or EDP-323 if approved.

  • Payers and reimbursement decision-makerssecondary

    Insurers and managed care organizations that determine access and pricing for any approved drug.

  • Licensing and development partnerssecondary

    Pharma or biotech partners that may in-license, co-develop, or commercialize Enanta assets.

Enanta is headquartered in Watertown, Massachusetts and operates as a U.S.-based R&D company...

  • •Headquartered in Watertown, Massachusetts, United States
  • •Royalty income depends on AbbVie's global HCV sales footprint
  • •Third-party manufacturing includes suppliers in China
  • •Clinical and regulatory activity is U.S.-centered but globally relevant
  • •No disclosed country-level revenue split in the excerpts

Enanta’s strategy is to use royalty cash flow from AbbVie to fund discovery and clinical development of new virology...

01
Advance RSV clinical programsshort-term

RSV is a large unmet-need market where clinical success could create partnering or commercialization value.

02
Expand immunology pipelinemedium-term

STAT6 inhibition could open a second therapeutic franchise beyond virology and diversify pipeline risk.

03
Monetize and manage IP through partnershipsmedium-term

Licensing can generate non-dilutive capital and reduce the need to build a full commercial organization.

Enanta is exposed to clinical development risk, partner concentration risk, and dependence on royalty income from a...

high

Dependence on AbbVie royalty revenue

A large share of current cash generation comes from MAVYRET/MAVIRET sales, so any decline in HCV demand directly reduces funding for R&D.

Scope
AbbVie HCV collaboration
Materiality
high
high

Clinical development failure

Zelicapavir, EDP-323, and STAT6 programs are still in development and may not show sufficient efficacy or safety.

Scope
RSV and immunology pipeline
Materiality
high
high

Third-party manufacturing and supply chain disruption

The company relies on external manufacturers, including in China, for APIs and clinical supply.

Scope
API sourcing and clinical trial materials
Materiality
high
medium

Competition from larger pharma and biotech companies

Competitors have greater resources, late-stage assets, and established commercial infrastructure.

Scope
HCV, RSV, HBV, and immunology markets
Materiality
medium
medium

Reimbursement and pricing pressure

Even approved drugs may face payer resistance, limiting uptake and realized economics.

Scope
Future commercial products
Materiality
medium
Royalty revenue recognition
Affects top-line volatility and comparability across periods
OMERS royalty sale agreement
Affects liquidity and cash flow analysis
R&D expense accruals
Can shift quarterly operating expense and margin
Fair value of Series 1 preferred stock
Affects balance sheet and non-cash fair value adjustments

ENANTA PHARMACEUTICALS INC

ENTA · Pharmaceutical Preparations

Entera Bio Ltd.

ENTX · Biological Products, (No Diagnostic Substances)

Envista Holdings Corp

NVST · Dental Equipment & Supplies

enGene Therapeutics Inc.

ENGN · Biological Products, (No Diagnostic Substances)

Sedana Medical

SEDANA.ST · Health Care

ANAPTYSBIO, INC

ANAB · Pharmaceutical Preparations

: 28/04/2026